安罗替尼辅助治疗对铂耐药复发性卵巢癌患者临床疗效及卵巢血流参数指标的影响  

Effect of Anlotinib Adjuvant Therapy on Clinical Efficacy and Ovarian Blood Flow Parameters in Patients with Platinum-resistant Recurrent Ovarian Cancer

作　　者：胡华 何大伟 张水芬 Hu Hua;He Dawei;Zhang Shuifen(Department of Obstetrics and Gynecology,Huanggang Huangmei County People's Hospital,Huanggang 435500,Hubei Province,China)

机构地区：[1]黄冈市黄梅县人民医院妇产科,湖北黄冈435500

出　　处：《中外医药研究》2024年第32期58-60,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:观察铂耐药复发性卵巢癌患者应用安罗替尼辅助治疗的临床效果及对卵巢血流参数指标的影响。方法:选取2023年4月—2024年3月黄梅县人民医院收治的96例铂耐药复发性卵巢癌患者进行研究,按照随机分组原则分为对照组(48例,应用盐酸多柔比星脂质体治疗)和观察组(48例,在对照组基础上应用安罗替尼辅助治疗)。比较两组临床治疗效果。结果:观察组疾病控制率高于对照组(P<0.001);治疗后,观察组糖类抗原125、糖类抗原199、人附睾蛋白4、搏动指数、阻力指数、收缩期峰值流速、B细胞1CLL/淋巴瘤2关联抗凋亡基因1、B细胞淋巴瘤-2基因指标均优于对照组(P<0.05);观察组不良反应发生率低于对照组(P<0.001)。结论:安罗替尼辅助治疗铂耐药复发性卵巢癌的效果理想,可有效控制患者病情,调节血清肿瘤标志物指标、卵巢血流参数指标、血清凋亡因子,治疗安全性较高。Objective:To observe the clinical effect of anrotinib adjuvant therapy in patients with platinum-resistant recurrent ovarian cancer and its influence on ovarian blood flow parameters.Methods:A total of ninety-six patients with platinum-resistant recurrent ovarian cancer admitted to Huangmei County People's Hospital from April 2023 to March 2024 were selected for this study.According to the principle of randomization,they were divided into control group(48 cases,treated with Doxorubicin hydrochloride liposome)and observation group(48 cases,treated with anlotinib on the basis of control group).The clinical therapeutic effect of the two groups was compared.Results:The disease control rate of observation group was higher than that of control group(P<0.001);after treatment,carbohydrate antigen 125,carbohydrate antigen 199,human epididymal protein 4,pulsation index,resistance index,systolic peak flow rate,B-cell 1CLL/lymphomat2-associated anti-apoptotic gene 1 and B-cell lymphomat-2 gene indexes in observation group were better than those in control group(P<0.05);the incidence of adverse reactions in observation group was lower than that in control group(P<0.001).Conclusion:The adjuvant treatment of antirotinib for platinum-resistant recurrent ovarian cancer has an ideal effect,can effectively control the patient's condition,regulate serum tumor markers,ovarian blood flow parameters,and serum apoptosis factors,and has a high therapeutic safety.

关 键 词：安罗替尼 铂耐药复发性卵巢癌 疾病控制率 血清肿瘤标志物 卵巢血流参数指标 

分 类 号：R737.31[医药卫生—肿瘤]